scholarly journals Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival

2012 ◽  
Vol 107 (7) ◽  
pp. 1075-1082 ◽  
Author(s):  
Y S Yap ◽  
G H Cornelio ◽  
B C R Devi ◽  
C Khorprasert ◽  
S B Kim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Impact On Survival ◽  
Positive Breast Cancer

scholarly journals Systemic Treatment Options for HER2-Positive Breast Cancer Patients with Brain Metastases beyond Trastuzumab: A Literature Review

Breast Care ◽  
2017 ◽  
Vol 12 (3) ◽  
pp. 168-171 ◽  
Author(s):  
Elena Laakmann ◽  
Volkmar Müller ◽  
Marcus Schmidt ◽  
Isabell Witzel
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Cancer Patients ◽  
Systemic Treatment ◽  
Treatment Options ◽  
Cytotoxic Agents ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

Background: The incidence of brain metastases (BM) in breast cancer patients has increased. Many retrospective analyses have shown that first-line treatment with trastuzumab prolongs survival in patients with HER2-positive BM. In contrast, the evidence for other therapies targeting HER2 for patients with BM is rare. Methods: The aim of this review is to update the reader about current systemic treatment options in patients with HER2-positive metastatic breast cancer with BM who had already received trastuzumab. A literature search was performed in the PubMed database in June 2016. 30 relevant reports concerning the efficacy of trastuzumab emtansine (T-DM1), lapatinib and its combination with other cytotoxic agents, pertuzumab and novel HER2-targeting substances were identified. Results: There is limited but promising evidence for the use of T-DM1 and pertuzumab in the treatment of BM. Up to now, most reported studies used lapatinib as treatment of HER2-positive breast cancer with BM, a treatment with only a modest effect and a high toxicity profile. The combination of lapatinib with cytotoxic agents seems to result in better response rates. Conclusion: Further prospective investigations are needed to investigate the efficacy of the established and novel HER2-targeting agents on BM in HER2-positive breast cancer patients.

Graded prognostic assessment (GPA) of HER2 positive breast cancer patients with brain metastases.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 589-589
Author(s):  
Ming Chi ◽  
Vyshak Alva Venur ◽  
Alireza Mohammad Mohammadi ◽  
Samuel T. Chao ◽  
G. Thomas Budd ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Prognostic Assessment ◽  
Graded Prognostic Assessment ◽  
Positive Breast Cancer

scholarly journals 64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients

2015 ◽  
Vol 5 (1) ◽  
Author(s):  
Hiroaki Kurihara ◽  
Akinobu Hamada ◽  
Masayuki Yoshida ◽  
Schuichi Shimma ◽  
Jun Hashimoto ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Cancer Patients ◽  
Pet Imaging ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

scholarly journals PO97 BRAIN METASTASES IN HER2- POSITIVE BREAST CANCER PATIENTS: A SINGLE INSTITUTE EXPERIENCE

The Breast ◽  
2015 ◽  
Vol 24 ◽  
pp. S55
Author(s):  
Tahir Mehmood ◽  
Asma Rashid ◽  
Muhammad Irfan ◽  
Sumera Nighat ◽  
Bilal Aziz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document